Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2 studies found for:    20823433 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Not yet recruiting Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer
Condition: Pancreatic Adenocarcinoma
Intervention: Drug: Preoperative modified FOLFIRINOX and postoperative gemcitabine
2 Completed Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: fluorouracil;   Drug: gemcitabine hydrochloride;   Drug: leucovorin calcium;   Other: clinical observation

Indicates status has not been verified in more than two years